Daytona Ultra-widefield Imaging Device from Optos plc Wins “Best Technology” at the 2014 European Mediscience Awards
LONDON, UK, 20 June 2014 - Optos plc (LSE: OPTS), a leading medical retinal imaging company, is pleased to announce that it’s Daytona ultra-widefield imaging (UWF) device has won “Best Technology” at the 2014 Mediscience Awards. The award covered the period dating 1 April 2013 to 31 March 2014 and required that the technology be innovative, well-funded and capable of significant commercial success. “This is a fantastic recognition of Daytona and our UWF technology as well as all the hard work of all of our employees to make it an outstanding success in the marketplace.” says Roy Davis, CEO of Optos, plc. Mr. Davis continues by stating, “Daytona was designed to allow the globalisation of the core Optos imaging technology, and to date over 2,000 Daytona devices are in active use which now represents over 30% of the Optos installed client base, a figure which has been achieved from a standing start.”
The European Mediscience Awards is a truly European affair. It is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The award was presented to Senior Non-executive Director of Optos, David Wilson on 19 June 2014 at the Hotel InterContinental.
Enquiries:
| Optos plc Roy Davis, CEO Rob Kennedy, CFO |
Tel: 01383 843 300 |
About Optos Plc
Optos has the vision to be The retina company. We aim to be recognised as a leading provider of devices and solutions to eyecare professionals for improved patient care. Optos' core devices produce ultra-widefield, high resolution digital images (optomap®) of approximately 82% of the retina, something no other device is capable of doing in any one image. Our acquisition of OPKO instrumentation in 2011 brought the group optical coherence tomography (“OCT”) diagnostic devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and conditions.
Optos’ widefield retinal imaging technology, combined with the specific data that can be derived from OCT images, has the potential to offer ophthalmologists and optometrists the most powerful tools for disease diagnosis and management. The optomap images provide enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. OCT delivers an image that shows a three dimensional, cross-sectional view of the retina in any particular area, typically in the central pole area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect.
Optos has a range of imaging devices that support different customer segments and patient levels: the P200 and 200Dx devices are concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C devices are designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA and 200Tx devices supports ophthalmologists and retinal specialists in the medical care market. In 2012 we introduced Daytona, our next generation imaging device. Daytona is a desk top device with multiple imaging modalities and was designed to enable us to globalise our ultra widefield technology. Our expanded product range includes visual acuity, perimetry and treatment laser products.
For more information please visit our website www.optos.com.